Magnesium sulfate Pregnancy and Breastfeeding Warnings
Magnesium sulfate Pregnancy Warnings
Magnesium sulfate has been assigned to pregnancy category D by the FDA. There is positive evidence of human fetal risk, but the potential benefits of using the drug in pregnant women in certain situations may be acceptable despite the risks.
Newborns may show signs of magnesium toxicity (i.e. respiratory and/or neuromuscular depression) if the mother has received intravenous magnesium sulfate prior to delivery (especially if for a period of longer than 24 hours). Equipment for assisted ventilation as well as intravenous calcium should be immediately available for the first 24 to 48 hours after delivery. One study has reported that maternal magnesium sulfate treatment is associated with reduced brain blood flow perfusion in preterm infants. However, intravenous magnesium sulfate did not lead to lower neonate Apgar scores in a study of women treated for preeclampsia even though the newborns cord level indicated hypermagnesemia. The mean cord magnesium level (5.3 mEq/100 mL) was equivalent to the mean maternal serum level. Cord serum magnesium levels do not usually correlate with infant toxicity. The Collaborative Perinatal Project monitored 50,282 mother-child pairs, 141 of which had been exposed to magnesium sulfate during pregnancy. No reports or evidence were found linking congenital birth defects with magnesium sulfate. A study of 7000 offspring of mothers treated for preeclampsia noted no adverse effects due to magnesium sulfate therapy in the fetuses or newborns. One study compared the newborn of women with pregnancy-induced hypertension who received magnesium sulfate with women who did not receive treatment. Neurologic behavior in the infants was similar in both groups except that the exposed group had decreased active tone of the neck extensors the day after birth. Long-term infusions of magnesium (such as those used for tocolysis) may lead to persistent hypocalcemia and congenital rickets in the fetus. Case reports of 2 women receiving 9 or 14 weeks of intravenous magnesium therapy prior to delivery noted bony abnormalities. Slight hypocalcemia occurred in one infant. Both infants were treated with intravenous calcium for 3 to 5 days and then given bottle feedings without added calcium or vitamin D. The only noted physical abnormality at 3 year follow-up was dental enamel hypoplasia in one infant. Fetal hypermagnesemia may have decreased parathyroid hormone release and lead to fetal hypocalcemia. The combination of in utero acquired magnesium sulfate and gentamicin (administered after birth) may lead to respiratory depression in the newborn. The mechanism of this interaction is not known. Animal studies have confirmed this drug interaction.
Magnesium sulfate Breastfeeding Warnings
Magnesium is excreted into human milk. Adverse effects in the nursing infant are unlikely. Magnesium sulfate is considered compatible with breast-feeding by the American Academy of Pediatrics.
Ten preeclamptic women received a 4 gram loading dose of magnesium sulfate, followed by a maintenance dose of 1 gram per hour for 24 hours. After 24 hours, the human milk magnesium levels were the same as those of control subjects. The breast-fed infant would receive only 1.5 mg more of magnesium than an infant whose mother did not receive magnesium sulfate prior to and for 24 hours after delivery.
- Magnesium Sulfate use while Breastfeeding (in more detail)
- magnesium sulfate Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.